Welcome to our dedicated page for Halozyme Therapeutics news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics stock.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company headquartered in San Diego, CA, focused on developing and commercializing innovative oncology therapies. The company's core mission is to enhance the efficacy of cancer treatments by targeting the tumor microenvironment, particularly through its lead investigational drug, pegph20. This drug aims to improve the penetration of co-administered cancer therapies into solid tumors, potentially making existing treatments more effective.
Halozyme's proprietary ENHANZE® drug delivery technology platform has garnered significant attention and partnerships with leading pharmaceutical companies such as Roche, Pfizer, Janssen, Baxalta, AbbVie, and Lilly. This technology facilitates the subcutaneous administration of biologics and small molecule compounds that are traditionally delivered intravenously, potentially allowing for quicker and more convenient therapy delivery.
The company has built a strong foundation of value-driving partnerships and continues to innovate in drug-device combination products using advanced auto-injector technology to improve patient convenience, comfort, and adherence. Halozyme's commercial portfolio includes proprietary products like Hylenex® and XYOSTED®, and ongoing product development in partnership with pharmaceutical companies such as Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Recent achievements highlight Halozyme’s growth and innovation. Notably, the U.S. FDA approved Takeda’s HYQVIA®, co-formulated with ENHANZE®, for the maintenance therapy of chronic inflammatory demyelinating polyneuropathy (CIDP), underscoring the potential of Halozyme’s technology to enhance treatment efficacy. Another milestone includes the Japanese Ministry of Health's approval of argenx's VYVDURA® for generalized myasthenia gravis, demonstrating global expansion and acceptance of ENHANZE®-enabled treatments.
Financially, Halozyme continues to show robust growth. The company reported strong revenue and earnings growth in the first quarter of 2024, reaffirming its positive financial guidance for the year. Halozyme also announced a new $750 million share repurchase program, indicating confidence in sustained growth.
Halozyme's efforts in maintaining an extensive patent portfolio, including the recent grant of European Patent No. 4269578 for its ENHANZE® rHuPH20 product, further solidify its market position and prospects for long-term revenue durability. The company's strategic collaborations and commitment to innovative patient solutions make it a significant player in the biopharmaceutical industry.
Halozyme Therapeutics has revised its 2020 financial guidance following a global collaboration agreement with Horizon Therapeutics. The company increased its revenue forecast to $265 million to $275 million, up from $250 million to $260 million, indicating a year-over-year growth of 35% to 40%. Earnings per share projections also rose to $0.90 to $0.95, compared to the prior estimate of $0.80 to $0.85. This positive adjustment is attributed to ongoing revenue-generating activities in the fourth quarter.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded chat will be accessible on November 25 via the company’s investor relations website. Halozyme focuses on innovative biopharmaceutical solutions, primarily using its proprietary ENHANZE® technology, which enhances drug delivery and has positively impacted over 400,000 patients globally. The company partners with major pharmaceutical firms to develop new therapies, enhancing patient experiences and outcomes.
Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen Pharmaceutical submitted applications to both the FDA and EMA for the approval of DARZALEX FASPRO™ subcutaneous formulation. This treatment, aimed at relapsed or refractory multiple myeloma patients, allows administration in 3-5 minutes, vastly reducing the time from the traditional intravenous method. The application is backed by positive results from the Phase 3 APOLLO study suggesting longer progression-free survival compared to the standard treatment. The full study results will be presented at the ASH Annual Meeting on December 6, 2020.
Halozyme Therapeutics (NASDAQ: HALO) has announced that key studies sponsored by Janssen Research & Development will be presented at the American Society of Hematology (ASH) Annual Meeting from December 5-8, 2020. The Phase 3 APOLLO study will feature an oral presentation on December 6 at 3:00 p.m. ET, discussing subcutaneous daratumumab with pomalidomide and dexamethasone in multiple myeloma patients. The ANDROMEDA study results will be presented on December 7, also in an oral format, along with four additional poster presentations.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported robust financial results for Q3 2020, achieving a revenue of $65.3 million, up from $46.2 million year-over-year. The growth was driven by $32.0 million in collaboration revenue and a 44% rise in royalties. The company's net income was $36.2 million, marking a significant turnaround from a net loss in the prior year. Halozyme also raised its full-year revenue guidance to $250 million-$260 million, reflecting a projected 28-33% growth. The company has repurchased $312.4 million in shares, reinforcing its commitment to capital return.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host a webcast for its third-quarter 2020 financial results on November 2, 2020, at 4:30 p.m. ET. The call, led by CEO Dr. Helen Torley, follows the release of the financial results for the quarter ending September 30, 2020.
Investors can register through a provided link, with a replay available for two weeks post-call. Halozyme utilizes its ENHANZE® technology, enhancing drug delivery, to partner with major pharmaceutical firms and positively impact patient outcomes globally.
Halozyme Therapeutics (NASDAQ: HALO) has expanded its collaboration with argenx, adding exclusive access to its ENHANZE® drug delivery technology for three new targets. This brings the total to six targets under the agreement initiated in February 2019. argenx is advancing the development of its FcRn antagonist efgartigimod and has also nominated a complement inhibitor targeting C2. The collaboration aims to improve patient experiences by enabling subcutaneous delivery options for various therapies. Halozyme derives revenues through milestones and royalties from these partnerships.
Halozyme Therapeutics (NASDAQ: HALO) announced that Roche presented data from the Phase 1b study evaluating atezolizumab (Tecentriq) for subcutaneous use through Halozyme's ENHANZE technology at the ESMO Virtual Congress 2020. The study, involving 67 patients with advanced non-small cell lung cancer, showed that the subcutaneous formulation was well-tolerated and had similar exposure to the intravenous version. This supports further development in the Phase 3 study, potentially improving treatment efficiency by reducing administration time.
Halozyme Therapeutics announced that Janssen Biotech submitted a supplemental Biologics License Application (sBLA) to the FDA for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to treat light chain (AL) amyloidosis, a serious disease with no approved therapies. The application is backed by positive results from the Phase 3 ANDROMEDA study, which achieved its primary endpoint. This sBLA is evaluated under the FDA's Real-Time Oncology Review program, aiming for expedited patient access to treatments. The approval process does not guarantee success.
FAQ
What is the current stock price of Halozyme Therapeutics (HALO)?
What is the market cap of Halozyme Therapeutics (HALO)?
What is Halozyme Therapeutics' main focus?
What is the ENHANZE® technology?
Who are Halozyme's key partners?
What recent approvals have Halozyme's technologies received?
What are some of Halozyme's proprietary products?
Where is Halozyme headquartered?
How does Halozyme's ENHANZE® technology benefit patients?
What is the significance of Halozyme's recent European patent grant?
What financial outlook did Halozyme recently provide?
What is pegph20?
